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Abstract
The recent interest and elucidation of the JAK/STAT signaling pathway created new targets
for the treatment of inflammatory skin diseases (ISDs). JAK inhibitors in oral and topical for-
mulations have shown beneficial results in psoriasis and alopecia areata. Patients suffering
from other ISDs might also benefit from JAK inhibition. Given the development of specific
JAK inhibitors, the expression patterns of JAKs in different ISDs needs to be clarified. We
aimed to analyze the expression of JAK/STAT family members in a set of prevalent ISDs:
psoriasis, lichen planus (LP), cutaneous lupus erythematosus (CLE), atopic dermatitis
(AD), pyoderma gangrenosum (PG) and alopecia areata (AA) versus healthy controls for
(p)JAK1, (p)JAK2, (p)JAK3, (p)TYK2, pSTAT1, pSTAT2 and pSTAT3. The epidermis car-
ried in all ISDs, except for CLE, a strong JAK3 signature. The dermal infiltrate showed a
more diverse expression pattern. JAK1, JAK2 and JAK3 were significantly overexpressed
in PG and AD suggesting the need for pan-JAK inhibitors. In contrast, psoriasis and LP
showed only JAK1 and JAK3 upregulation, while AA and CLE were characterized by a sin-
gle dermal JAK signal (pJAK3 and pJAK1, respectively). This indicates that the latter dis-
eases may benefit from more targeted JAK inhibitors. Our in vitro keratinocyte psoriasis
model displayed reversal of the psoriatic JAK profile following tofacitinib treatment. This
direct interaction with keratinocytes may decrease the need for deep skin penetration of
topical JAK inhibitors in order to exert its effects on dermal immune cells. In conclusion,
these results point to the important contribution of the JAK/STAT pathway in several ISDs.
Considering the epidermal JAK3 expression levels, great interest should go to the investi-
gation of topical JAK3 inhibitors as therapeutic option of ISDs.
Introduction
Inflammatory skin diseases (ISDs) are very prevalent worldwide and have a serious impact on
the patients’ quality of life. However, treatment options remain scarce with corticosteroids
being the main topical option. Recent advances on the role of cytokines in the pathophysiology
of immune mediated inflammatory diseases lead to the understanding that many pro-
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inflammatory interleukins use JAK/STAT components for signal transduction [1, 2]. Briefly,
the JAK/STAT signaling pathway transmits information from extracellular chemical signals to
the nucleus resulting in DNA transcription. Binding of ligands, such as interferon and interleu-
kins, to their specific transmembrane receptors activate associated JAKs. Subsequently, acti-
vated JAKs (Janus kinases) phosphorylate tyrosine residues on the receptor, creating docking
sites for latent STATs (Signal Transducer and Activator of Transcription). After recruitment of
STAT to the receptor, they are also phosphorylated by JAKs. Activated STATs migrate to the
nucleus of the cell and promote gene transcription or induction [3, 4]. In mammals, the JAK/
STAT family consists of 4 JAK members (JAK1, JAK2, JAK3 and TYK2) and 7 STAT members
(STAT1, STAT2, STAT3, STAT4, STAT5a, STAT5b, STAT6) [3]. The JAKs are selectively acti-
vated by different receptors and have, therefore, distinct in vivo roles [4]. JAK1 is mainly acti-
vated by type II cytokine receptors. JAK2 is crucial in transducing signals for cytokine
receptors involved in hematopoiesis (erythropoietin, thrombopoietin and haematopoietic cell
development cytokines). JAK3 is mainly expressed in B and T lymphocytes, and TYK2 associ-
ates commonly with other JAKs [5].
The recent discovery of the JAK/STAT signaling pathway opened a new window of oppor-
tunity for the treatment of ISDs and promoted the development of drugs that block JAK activa-
tion [1, 2]. The kinase domain of JAKs makes them an easier pharmacological target compared
to STATs, which do not have catalytic activity [3]. One of the advantages of JAK inhibitors is
their structure. They are small molecules, which can easily penetrate the epidermal barrier and
therefore be used in topical formulations [6]. In psoriasis, the involvement of JAKs has been
shown and enabled the assessment of oral and topical JAK inhibitors as therapeutics. Tofaciti-
nib, a pan-JAK inhibitor with predominant anti-JAK3 effect, has shown promising results in
the treatment of psoriasis both orally [7] and topically [8]. Ruxolitinib, a JAK1/2 inhibitor used
in the treatment of hematological diseases, has been tested in topical formulations to treat mild
to moderate psoriasis, with favorable results [9]. However, the knowledge of the cutaneous JAK
involvement in the ISDs is scarce and mostly based on in vitro or animal model analysis. In
some of the most prevalent ISDs, such as mucosal lichen planus, cutaneous lupus erythemato-
sus, atopic dermatitis and alopecia areata, Th1 and/or Th17 responses have been shown [10–
16]. The main cytokines involved in Th1 and Th17 responses use JAKs for signaling [1, 17, 18].
Additionally, not only T cells, but also keratinocytes, dendritic cells, mast cells, eosinophils and
macrophages could be activated [19, 20]. Due to the need of further elucidation of the JAK sig-
naling in the ISDs, we aimed to analyze the cutaneous JAK/STAT expression in 6 prevalent
ISDs. The set of ISDs comprises psoriasis, lichen planus (LP), cutaneous lupus erythematosus
(CLE), atopic dermatitis (AD), alopecia areata (AA) and pyoderma gangrenosum (PG).
Methods
Human skin biopsies
Skin biopsies from patients with unequivocal clinical and histopathological diagnosis of psoria-
sis (n = 23), LP (n = 23; 8 cutaneous lichen planus, 9 lichen planopilaris, 6 mucous lichen pla-
nus), CLE (n = 22; 12 chronic discoid lupus, 6 subacute lupus, 1 acute lupus, 3 lupus tumidus),
AD (n = 20), AA (n = 7), and PG (n = 10) were retrospectively collected from the Dermatology
Department tissue biobank at the Ghent University Hospital, Belgium. Skin biopsies from
healthy volunteers (n = 18) were used as controls. Additionally, lesional zskin biopsies from
psoriasis patients (n = 10) and healthy controls (n = 10) were preserved in RNAlater solution
(Life Technologies, Belgium) at -20°C. All skin biopsies included in this study were derived
from patients who haven’t been receiving any systemic/topical immunosuppressant or immu-
nomodulator during a minimum of 15 days before the excision. This study was carried out in
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accordance with the principles expressed in the Declaration of Helsinki. The protocol was
approved by the Committee of Ethics of the Ghent University Hospital-Belgium (number:
B670201318616/B670201318860). Written informed consent was obtained from the involved
subjects before the skin biopsy was done for the qPCR analysis. Regarding the retrospective
material, the patients were informed about the research and should contact the service only if
they disagreedwith the research.
Immunohistochemistry
Biopsies were processed for immunohistochemistry and deparaffinized sections (4 μm) were
stained using Dako immunohistochemistry products (Heverlee, Belgium).Antigens were
retrieved using target retrieval solution (pH 6.1 or 9, 97°C) for 10–30 minutes. Slides were
blocked using EnVision FLEX peroxidase-blocking reagent and incubated with the primary
antibody during 1 h at room temperature. Detectionwas performed using the EnVision FLEX/
HRP detection reagent and AEC+. After counterstaining using EnVision Flex Haematoxylin,
slides were mounted and images were taken using Zeiss microscope (Axiophot), camera (Axio-
cam) and software (Axiovision) (Zeiss, Belgium).
The antibodies and their dilutions, pH and duration of antigen retrieval used, were consecu-
tively: JAK2 (#3230, 1/50, pH9, 10’), pSTAT1 (#9167, 1/50, pH9, 10’) and pSTAT3 (#9145, 1/
50, pH9, 10’), all rabbit monoclonal antibodies from Cell Signaling (Bioké, The Netherlands);
JAK1 (ab47435, rabbit polyclonal, 1/200, pH9, 20’), JAK3 (ab61198, rabbit polyclonal, 1/50,
pH9, 30’), TYK2 (ab115691, rabbit polyclonal, 1/50, pH6.1, 30’) and pJAK2 (ab32101, rabbit
monoclonal, 1/200, pH9, 20’) (Abcam, United Kingdom); pJAK1 (sc-101716, 1/50, pH9, 30’)
and pTYK2 (sc-11763, 1/50, pH6.1, 30’) rabbit polyclonal antibodies (Santa Cruz, Germany);
pJAK3 (ABIN742868, 1/200, pH9, 30’) and pSTAT2 (bs-3428R, 1/100, pH9, 10’) rabbit poly-
clonal antibodies from Bioss Antibodies (Bio-connect, The Netherlands).
Antibody validation
In order to validate the antibodies’ performance, positive control samples were included: breast
carcinoma tissue for JAK1, JAK2, pJAK1, pSTAT2; cutaneous T cell lymphoma for JAK3,
pJAK2 and pJAK3, Crohn’s disease and duodenum for respectively TYK2 and pTYK2, and
psoriasis skin for pSTAT1 and pSTAT3 staining. Isotype controls were used to exclude anti-
bodies which represented nonspecific binding.
In vitro psoriasis model
To validate the epidermal staining profile, we used the monolayer in vitro psoriasis model
describedby Bracke et al using keratinocytes from a healthy donor.[21]. After isolated, the ker-
atinocytes were cultured in 6 well culture plates containing keratinocyte growth medium
(KGM, 2ml per wells) during 48h, when they reached at least 70% of confluence. Subsequently,
the keratinocytes were divided in three groups and cultured during more 48h (mediumwas
changed). Group 1 was induced to normal keratinocyte differentiation by culture in KGM and
used as control; in group 2, psoriasis-associated features were induced by culture in KGM sup-
plemented with 5% FBS (fetal bovine serum) and a pro-inflammatory cytokinesmixture
(10ng/ml IL-1α (Life Technologies, Belgium), 5 ng/mL IL-6, 5 ng/mL TNF-α, 10 ng/mL IL-
17A [21] and 20 ng/mL IL-22 (all from Peprotech, United Kingdom)), and group 3 was
induced to psoriasis-associated features as group 2 and treated with tofacitinib 1μM tofacitinib
(Sigma-Aldrich, Belgium), which was added to the medium (simultaneously induction of pso-
riasis features and treatment with a JAK inhibitor). After 48 hours of induction, the cells were
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colleted, after removal of the medium and addition of trypsin EDTA, and fixed and embedded
in paraffin.
Briefly, the cells were pelleted by centrifugation (400 rpm, 10’ at room temperature), fixed
in 10% buffered formalin (Sigma-Aldrich, Belgium) during 2 h at room temperature and pel-
leted once more. Cell pellets were resuspended in 300 μL PBS and heated to 65°C in a warm
water bath for less than 10 minutes. Next, 600 μL of melted agarose (3% low melting point
agarose in PBS, at 65°C—Difco, United States) was added to the cells followed by immediate
centrifugation. After gelation on ice, the gelled pellets were processed to paraffin blocks.
Immunohistochemistry staining for pJAK1, pJAK2, pJAK3 and pTYK2was done as described
above.
Staining analysis and classification
The 18 healthy controls and 20 psoriatic skin biopsies were stained with the complete JAK/
STAT antibody panel. Regarding the other ISDs, samples of 10 patients (7 in the case of alope-
cia areata) were stained for JAK2, JAK3, TYK2, pJAK2, pJAK3, pTYK2. For JAK1, pJAK1 and
the pSTATs, all the biopsies were stained (23 from LP, 22 from CLE, 20 from AD, 7 from AA
and 10 from PG). Slides were blindly analyzed using Image J software.
In dermal inflammatory cells, the staining was classified as either ‘positive’ or ‘negative’. In
the epidermal part, a distinctionwas made between cytoplasmatic and nuclear staining.When
the staining was localized in the cytoplasm, the intensity and extent of staining were scored
(extent 0: negative, 1: only basal layer, 2:½ of the epidermal thickness and 3:>½ of the epi-
dermal thickness). For nuclear staining, the amount of stained cells per epidermal area (mm2)
was counted.
Statistical analysis
Statistical analysis was performed comparing each dermatosis with the healthy controls using
SPSS Statistics 22. Differences between the groups were assessed by Kruskal-Wallis ANOVA
for continuous variables. A Chi-Square test was used for the analysis of the not continuous var-
iables. The results were considered statistically significant for p 0.05.
RNA isolation and real-time qPCR analysis of skin biopsies
Untreated lesional psoriatic skin biopsies and healthy human skin obtained from patients
undergoing plastic surgery were collected for JAK/STAT gene expression analysis. RNA isola-
tion of the biopsies followed by RNA quality control and cDNA synthesis was done at Bioga-
zelle (Biogazelle NV, Belgium). Briefly, the TissueLyser LT was used for the disruption and
homogenization of the biopsies, prior to RNA extractionwith the miRNeasy micro kit accord-
ing to manufacturer’s recommendation (Qiagen, Belgium). RNA integrity was assessed by
means of Experion automated electrophoresis system (Bio-Rad, Belgium). The software algo-
rithm was used to calculate the RNA Quality Index (RQI) based on 28S/18S ribosomal RNA
ratio. RNA concentrations were high (between 300 and 5500 ng/μL for a 15 μL eluate) and
RNA integrity was acceptable (RQI: 6 to 9.3). The absence of gDNA was confirmed in all sam-
ples. cDNA synthesis was performed using the iScript Advanced cDNA Synthesis Kit (Bio-
Rad, Belgium)with 800 ng as total RNA input. The cDNA quality of each sample was assessed
by means of two human universally expressed genes. cDNA synthesis failed for one control
sample which was excluded for further analysis. A geNorm pilot study was performed at Bioga-
zelle to select proper, stably expressed reference genes for data normalization using a set of 8
candidate reference genes on all 19 samples. B2M and PP1A were identified as most stable ref-
erence genes. Therefore, the geometricmean of these two genes was used in order to calculate
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the optimal normalization factor needed for data normalization. qPCR-based gene expression
analysis of JAK1, JAK2, JAK3, TYK2, STAT1, STAT2, STAT3, and the reference genes was done
by use of validated PrimePCR assays (Bio-Rad, Belgium).All measurements were performed in
384-well plates in a reaction volume of 5 μL (with 5 ng cDNA input) using SYBR Green I. Each
PCR was done in duplicate. Data-analysis was done in Biogazelle’s qBase+ software [22]. Due
to the presence of high Cq values (> 30) or missing values for genes of interest, one psoriasis
and two control samples were excluded for statistical analysis. Therefore, 9 psoriasis samples
and 8 control samples were analyzed by the Mann-Whitney U test (2-tailed) in qBase+. The
results were considered statistically significant for p 0.05.
Results
In total 143 biopsies were analyzed (n = 123 immunohistochemistry;n = 20 qPCR analysis).
The demographics for each disease group are summarized in Table 1.
JAK/STAT expression in ISD skin biopsies
All 4 JAKs and their corresponding phosphorylated forms were positive in the epidermis and
dermis of investigated diseases (Figs 1 and 2). They showed expression in the cytoplasm and
along the cell membrane of keratinocytes, with the exception of pJAK2 which was only present
in the nucleus of the cells (Fig 2 insert). In addition to the cytoplasmatic localization, TYK2
and pTYK2were also expressed in the nucleus, with pTYK2 nuclear expression beingmore
pronounced than the cytoplasmatic staining (Figs 1 and 2 insert). These data confirm previous
reports on the intranuclear localization of pJAK2 and pTYK2, though their nuclear function
remains to be clarified [23, 24]. Additional studies are necessary to clarify the intranuclear
function of JAKs. Furthermore, in all the diseases, a perinuclear localization of JAK2, JAK3 and
pJAK3 was observed in some of the slides. The cytoplasmic and nuclear localization of the
pJAKs in the epidermis was confirmed in in vitro cultured keratinocytes.
As expected, pSTAT1, 2 and 3 are located into the nucleus of keratinocytes and/or dermal
inflammatory cells, where they bind a DNA-recognition motif called gamma-activated sites
(GAS) in the promoter region of cytokine-inducible genes and activate transcription [3].
Table 1. Demographics of the patients. The demographics for each disease group are comparable to the control group, except for AD.
Age (mean) P value(vs controls, Kruskal-Wallis ANOVA) Men/women (%) P value(vs controls, Chi-Square)
Immunohistochemistry
Psoriasis (= 23) 49.1±19.5 years (range 17–90) NS 47.8%/52.2% NS
LP (n = 23) 49.5±14.9 years (range 23–73) NS 34.8%/65.2% NS
CLE (n = 22) 49±16 years (range 17–76) NS 50%/50% NS
AD (n = 20) 26.1±23.3 years (range 0.7–
74)
p = 0.035 42.9%/57.1% NS
AA (n = 07) 47±24.4years (range 15–82) NS 50%/50% NS
PG (n = 10) 56.2±18.5 years (range 34–84) NS 40%/60% NS
Controls
(n = 18)
50.8±20 years (range 17–80) / 38.9%/61.1% /
qPCR
Psoriasis (= 9) 49.2
Controls (= 8) 52.9
NS = not statistically significant. LP = lichen planus, CLE = cutaneous lupus erythematosus, AD = atopic dermatitis, AA = alopecia areata, PG = pyoderma
gangrenosum.
doi:10.1371/journal.pone.0164080.t001
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Various patterns of epidermal JAK/STAT expression in diseased versus
healthy skin
In the epidermis, JAK3 but mainly it phosphorylated form showed a higher expression in all
ISDs except in CLE (p value for the pJAK3 intensity analysis for AD, AA and PG was, respec-
tively: 0.018;< 0.001 and 0.018). JAK1 and pJAK1 were only significantly overexpressed in PG
(p = 0.013 for JAK1, p = 0.024 for pJAK1). No significantly different expression was seen for
JAK2 and pJAK2 (Figs 3 and 4) in any of the investigated ISDs. Conversely, TYK2 and pTYK2
Fig 1. JAK1, JAK2, JAK3 and TYK2 immunohistochemical localization in the epidermis. Similar expression was seen in all studied
diseases: JAK1, 2 and 3 were expressed in the cytoplasm of the keratinocytes and TYK2, besides cytoplasmic expression, had nuclear
expression of TYK2 (arrow). Original magnification x 200. Pso = psoriasis, LP = lichen planus, CLE = cutaneous lupus erythemathosus,
AD = atopic dermatitis, AA = alopecia areata, PG = pyoderma gangrenosum.
doi:10.1371/journal.pone.0164080.g001
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was underexpressed in the epidermis of psoriasis, LP, CLE and PG (Figs 3 and 4). In AA and
PG, TYK2 epidermal intensity was higher compared to control skin, although pTYK2was
underexpressed (Figs 3 and 4).
Strong pSTAT2 overexpression was present in AD, AA and PG (p = 0.03,< 0.001 and 0.009
respectively) and pSTAT3 in psoriasis, AD and PG (p = 0.034, 0.002 and 0.001 respectively)
while there was no obvious pSTAT1 signal in de epidermal layer (Fig 4). Thus, LP shows no
differences in epidermal pSTAT expression compared to healthy skin. Moreover, there was no
Fig 2. PhosphoJAK1, pJAK2, pJAK3 and pTYK2 immunohistochemical localization in the epidermis. Cytoplasmic expression of
pJAK1, pJAK3 and pTYK2. Intranuclear expression of pJAK2 and pTYK2 (arrows). Similar expression was seen in all studied diseases.
Original x 200. Pso = psoriasis, LP = lichen planus, CLE = cutaneous lupus erythemathosus, AD = atopic dermatitis, AA = alopecia areata,
PG = pyoderma gangrenosum.
doi:10.1371/journal.pone.0164080.g002
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increased epidermal expression of any JAK/STAT member in lupus, except for a slight increase
in pSTAT3. Even after excluding lupus tumidus, a dermal form of lupus, the results remained
unchanged.
Different expression of JAK/STAT members in dermal inflammatory
cells
Compared to healthy skin, the expression of both pJAK1 (p-value Pso: 0.002, LP: 0.01, CLE:<
0.001, AD: 0.002, PG: 0.004) and pJAK3 (p-value Pso: 0.003, LP: 0.001, AD:< 0.001, AA:
0.002, PG:< 0.001) was significantly enhanced in the dermal inflammatory cells of most stud-
ied diseases (Fig 3, Table 2). This overexpression was more pronounced than in the epidermal
keratinocytes. The expression of (p)TYK2 in the inflammatory cells of ISDs was comparable to
that of healthy skin, with a significant underexpression of TYK2 in LP (p< 0.001). None of the
ISDs is characterized by an increased expression of JAK2, however pJAK2 was overexpressed
in AD (p = 0.042) and PG (p = 0.009). Phospho-STAT expression in dermal inflammatory
cells was highly dependent on the type of ISD (Fig 3, Table 2).
Fig 3. Overview of JAK/STAT protein (by immunohistochemistry) expression in the studied inflammatory skin
diseases as compared to healthy skin. Pso = psoriasis, LP = lichen planus, CLE = cutaneous lupus erythemathosus,
AD = atopic dermatitis, AA = alopecia areata, PG = pyoderma gangrenosum, epid ext = epidermal extent. NS = not
statistically significant.
doi:10.1371/journal.pone.0164080.g003
JAK3 and Inflammatory Skin Diseases
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Fig 4. SPSS statistical analysis of the keratinocyte staining compared with control (staining intensity for pJAK1 and pJAK3 and
density of the positively stained cells for pJAK2, pTYK2, pSTAT1, pSTAT2 and pSTAT3). Pso = psoriasis, LP = lichen planus,
CLE = cutaneous lupus erythemathosus, AD = atopic dermatitis, AA = alopecia areata, PG = pyoderma gangrenosum, epid ext = epidermal
extent. NS = not statistically significant. * p0.05 ** p0.001.
doi:10.1371/journal.pone.0164080.g004
JAK3 and Inflammatory Skin Diseases
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qPCR analysis of JAK/STAT expression in psoriasis confirms JAK3
overexpression
The expression of JAK/STATs in psoriatic skin was further elucidated by qPCR (Fig 5). Com-
pared to healthy skin, JAK3 (p = 0.024) was significantly overexpressed, while JAK2 (p = 0.001)
and TYK2 (p = 0.604) exhibited a decreased expression. These results are in agreement with
the JAK immunohistochemistry expression profile (Fig 3). Overall, the JAK1 expression in pso-
riatic skin was lower than healthy controls (p = 0.02). Regarding STATs, qPCR results indi-
cated overexpression of STAT3 (p = 0.052) and STAT1 (p = 0.005) in psoriasis (Fig 5).
Stimulation and inhibition experiments
We used our previously developed in vitro psoriasis model [21] to confirm the expression pat-
terns observed in the psoriatic biopsies. A psoriatic phenotype was induced in keratinocytes as
previously describedby our group (Fig 6). A marked pJAK3 overexpression was found with a
less intense pJAK1 induction corresponding to the psoriasis biopsy analysis. A subsequent
treatment with tofacitinib showed reversal of pJAK3 and pJAK1 expression demonstrating a
direct interaction of JAK inhibitors with psoriatic keratinocytes.
Discussion
To our knowledge, this is the first study investigating the expression of the JAK/STAT compo-
nents in a panel of inflammatory skin diseases using human skin diseasematerial. Overall, the
Table 2. Percentage of JAK/STAT family positivity (in grey)/negativity in dermal inflammatory cells of ISDs comparing to controls.
Controls Pso LP CLE AD AA PG
JAK1 Positive(%) 26(4/15) 64(9/14) 61*(13/21) 50(10/20) 50(10/20) 42(3/7) 80*(8/10)
Negative(%) 74(11/15) 36(5/14) 29(8/21) 50(10/20) 50(10/20) 68(4/7) 20(2/10)
pJAK1 Positive(%) 43.75(7/16) 94,7*(18/19) 85,71*(18/21) 100*(20/20) 95*(19/20) 71.4(5/7) 100*(10/10)
Negative(%) 56.25(9/16) 5.26%(1/19) 14.29(3/21) 0 5(1/20) 28.6(2/7) 0
JAK2 Positive(%) 100(18/18) 100(20/20) 100(10/10) 100(10/10) 100(10/10) 85(6/7) 100(10/10)
Negative(%) 0 0 0 0 0 15(1/7) 0
pJAK2 Positive(%) 47(8/17) 58.8(10/17) 80(8/10) 60(6/10) 90*(9/10) 71(5/7) 100*(10/10)
Negative(%) 53(9/17) 41.2(7/107) 20(2/10) 40(4/10) 10 (01/10) 29(2/7) 0
JAK3 Positive(%) 11(2/18) 13(2/15) 10(1/10) 40(4/10) 70*(7/10) 14.3(1/7) 90*(9/10)
Negative(%) 89(16/18) 87(13/15) 90(9/10) 60(6/10) 30(3/10) 85.7(6/7) 10(1/10)
pJAK3 Positive(%) 5,56(1/18) 52,63*(10/19) 70*(7/10) 20(2/10) 80*(9/10) 71.4*(5/7) 80*(8/10)
Negative(%) 94,44(17/18) 47,37(9/19) 30(3/10) 80(8/10) 20(1/10) 28.6(2/7) 20(2/10)
TYK2 Positive(%) 100(17/17) 100(19/19) 20*(2/10) 100(10/10) 100(10/10) 100(7/7) 100(10/10)
Negative(%) 0 0 80(8/10) 0 0 0 0
pTYK2 Positive(%) 94(17/18) 83(15/18) 100(10/10) 90(9/10) 100(10/10) 100(7/7) 100(10/10)
6(1/18) 17(3/18) 0 10(1/10) 0 0 0
pSTAT1 Positive(%) 12,5(2/16) 41(7/17) 59*(13/22) 84.2*(16/19) 50*(10/20) 0 80*(8/10)
Negative(%) 87.5(14/16) 59(10/17) 41(9/22) 15.8(3/19) 50(10/20) 100(7/7) 20(2/10)
pSTAT2 Positive(%) 29.4(5/17) 55(10/18) 47.6(11/21) 0 85*(17/20) 71(5/7) 100*(10/10)
Negative(%) 70.6(12/17) 45(8/18) 52.4(10/21) 100(20/20) 15(3/20) 29(2/7) 0
pSTAT3 Positive(%) 43.7(7/16) 62.5(10/16) 50(10/20) 65(13/20) 80*(16/20) 14.2(1/7) 40(4/10)
Negative(%) 56,3(9/16) 37.5(6/16) 50(10/20) 35(7/20) 20(4/20) 85.8(6/7) 60(6/10)
Pso = psoriasis, LP = lichen planus, CLE = cutaneous lupus erythematosus, AD = atopic dermatitis, AA = alopecia areata, PG = pyoderma gangrenosum,
* = significant expression.
doi:10.1371/journal.pone.0164080.t002
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JAK3 pathway was most upregulated followed by JAK1 and to a lesser extent JAK2. In the epi-
dermal layer, JAK3 was overexpressed in all ISDs except CLE indicating its crucial role in
inflammatory keratinocytes. This suggests that JAK3 inhibition is the most promising
approach for topical application as it can directly reverse the JAK profile of keratinocytes. In
our in vitro psoriasis model we showed that tofacitinib directly inhibits pJAK3 and pJAK1
expression in psoriatic keratinocytes. This implies that topical treatment with tofacitinib may
exert a direct impact on the psoriatic phenotype independent of its activities on infiltrating
immune cells. This indicates that deep dermal infiltration of topical JAK inhibitors, increasing
the likelihood of systemic absorption, might not be necessary.
Downstream, pSTAT2 and pSTAT3 are strongly expressed while no signs of STAT1 activa-
tion were found. The importance of STAT3 in inflammation has already been demonstrated. It
Fig 5. JAK/STAT mRNA levels in human skin biopsies from psoriasis compared to healthy controls illustrates JAK3, STAT1 and
STAT3 overexpression. * p0.05.
doi:10.1371/journal.pone.0164080.g005
JAK3 and Inflammatory Skin Diseases
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has been proven that STAT3 plays a role in keratinocyte differentiation and proliferation, is
activated in psoriatic lesions [25–27] and is a therapeutic target for the treatment of psoriasis
[27]. This suggests that topical application of JAK inhibitors would mainly act on the STAT3
cascade. The role of STAT2 is still unknown, but it has been suggested that STAT2 plays a role
in the activation of STAT1 and STAT3 [28]. In the dermal layer, the inflammatory immune
cells in most ISDs showed expression of all JAKs, with the exception of TYK2, although the
subsequent STAT signaling was dependent on the type of skin disease.
Our results indicate that psoriasis is mainly a JAK3 and JAK1 driven disease with a pre-
dominance of STAT3 signaling. STAT3 upregulation was seen in our qPCR analysis of
Fig 6. Immunohistochemical staining of normal keratinocytes (KCs) and psoriasis induced keratinocytes (Pso
KCs) with or without tofacitinib treatment. The pJAKs expression in Pso KCs was similar and summarizes the one
observed in the epidermis of the psoriasis skin biopsies. Strong pJAK3 expression and weak positive pJAK1 expression
was induced by psoriasis stimulation and inhibited after treatment with tofacitinib. Phospho-JAK2 and pTYK2 expression
did not change neither with psoriasis stimulation nor with the treatment. Note the cytoplasm localization of pJAK1 and
pJAK3 and the nuclear localization of pTYK2 in the keratinocytes. As pJAK2 was negative in all conditions, the localization
of the staining could not be analysed. Original magnification x200.
doi:10.1371/journal.pone.0164080.g006
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psoriatic samples. These findings corroborate with previous reports [26]. It has been shown
that STAT3 is involved in the upregulation of keratin 17, a hallmark of psoriasis, in keratino-
cytes following IL-17A stimulation [29]. In vitro, JAK3/STAT3 signaling acts as a target in
the treatment of psoriasis models [30, 31]. Tofacitinib, one of the most investigated JAK
inhibitors in the treatment of psoriasis, shows impressive beneficial responses with JAK3 as
their predominant target [7, 8]. Nonetheless, ruxolitinib, a JAK1/2 inhibitor, has also proven
its efficacy [9].
AA and LP also displayed a strong JAK3 expression. In AA, JAK1 and JAK2 were to a lesser
extent also elevated. The resulting downstream cascade seems based on the expression levels
mainly conducted by pSTAT2. This is remarkable as AA is considered to be a IFN-γ driven dis-
ease which would result in JAK1, JAK2 and STAT1 activation. In this regard, it is important to
notice that the landmark paper of Xing et al [32] did also found JAK3 as the only JAK overex-
pressed in human AA compared to controls. Moreover, in their mice experiments JAK3 inhibi-
tion also slightly outperformed JAK1/JAK2 antagonism. In a case report, a patient receiving
tofacitinib for psoriasis experienced remission of his longstanding alopecia universalis [33].
Currently, there are phase II trials ongoing to assess tofacitinib in alopecia areata
(NCT02197455, NCT02553330).
Little is known about JAK expression in LP. Nonetheless, the JAK3 and JAK1 overexpres-
sion which was especially present in the inflammatory infiltrate indicate that JAK1/3 inhibi-
tion might be a successful approach in LP. In CLE, only a JAK1 overexpression was found
in the dermis. This is in accordance with the results of Li et al involving patients with sys-
temic lupus erythematosus displaying pSTAT1 protein activation in their inflammatory
malar rash [34].
In AD an PG, all three JAKs and STATs were overexpressed. As PG is a highly inflamma-
tory disorder this might not be surprising. In AD, JAK research is still in its early phase. None-
theless, murine experiments and a small human trial demonstrated the potential of tofacitinib
in recalcitrant atopic dermatitis [35, 36]. In atopic dermatitis, IL-4 is the main involved inter-
leukin [20] and may phosphorylate different JAKs in several cell types [37]. In human B lym-
phocytes, IL-4 induces phosphorylation of JAK1 and JAK3 [38].
In the studied diseases, JAK2 did not emerge as pivotal therapy target as pJAK2 was only
overexpressed in the inflammatory dermal cells of AD and PG. Regarding the systemic JAK
inhibitors, analysis of clinical trials using JAK inhibition in the treatment of immune mediated
inflammatory diseases attributed hematological side effects to JAK2 blockade and suggested
selective JAK1/3 inhibition to increase efficacy and safety [39]. Our results indicate that the
role of JAK2 in ISD pathophysiology is probably limited, considering the low expression of
JAK2 in ISDs.
A striking reduced expression of TYK2 and pTYK2was found at the epidermal level. The
importance of TYK2 in inflammatory diseases is based on genetic polymorphisms and murine
experiments with knockout mice demonstrating its role in IL22 and IL23-mediated signaling
in psoriasis [40]. However, increased TYK2 expression has been scarcely reported and TYK2
downregulatedmRNA has been previously observed in psoriasis [26]. This suggests a complex
regulation of TYK2 in vivo.
This study of JAK/STAT expression in some prevalent ISDs was retrospective, what pre-
vented the collection of all clinical characteristics of the patients, and had a small sample size.
Nevertheless, there was a comparable population among the groups (except for AD, which
affects younger patients) and the immunohistochemical findings were validated by qPCR for
psoriasis.Moreover, we conducted an extensive validation of the used antibodies by cell stimu-
lation and inhibition experiments.
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Conclusion
The development of alternative strategies in the treatment of ISDs is desirable, as there is an
unmet therapeutic need. In this context JAK blockers have emerged as a promising option for
topical or systemic therapy. The topical formulation makes these drugsmore attractive for der-
matological purposes as they offer an improved safety profile. Our study evidenced that pan-
JAK inhibitors seem the most appropriate approach in PG and AD, based on the JAK expres-
sion levels. In contrast, AA, psoriasis and LP carrymainly a JAK3 signature which suggests
that specific JAK3 inhibition could be sufficient. In CLE, further research on the efficacy of
JAK1 inhibitors is warranted. Considering the epidermal expression levels, our results show
most evidence for topical JAK3 inhibitors in ISDs.
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